Cancer Science & Therapy

ISSN: 1948-5956

Open Access

Current Issue

Volume 13, Issue 4 (2021)

    Commentary Pages: 1 - 1

    cancer stems cells and drug resistance with conventional cancer therapies

    Philipa Aggrey

    Cancer cells are cells that divide relentlessly, forming solid tumors or flooding the blood with abnormal cells. Cell division is a normal process used by the body for growth and repair. A parent cell divides to form two daughter cells, and these daughter cells are used to build new tissue or to replace cells that have died because of aging or damage. Healthy cells stop dividing when there is no longer a need for more daughter cells, but cancer cells continue to produce copies. They are also able to spread from one part of the body to another in a process known as metastasis.

    Perspective Article Pages: 1 - 1

    Hormones and behavior: A psychological approach of Hormone- interactions

    Birago Anastasia

    A hormone is any member of a class of signaling molecules in multicellular organisms that are transported to distant organs to regulate physiology and / or behavior. Hormones are required for the correct development of animals, plants and fungi. The lax definition of a hormone (as a signalling molecule that acts distant from its site of production) means that many different classes of molecule can be defined as hormones. Among the substances that can be considered hormones, are eicosanoids (e.g. prostaglandins and thromboxanes), steroids (e.g. oestrogen and brassinosteroid), amino acid derivatives (e.g. epinephrine and auxin), protein / peptides (e.g. insulin and CLE peptides) and gases .

    Research Pages: 1 - 4

    Management of Hodgkin's Disease, Ino Experience 2014- 2016

    Mosse B. A. Wilfried*, Kietga Georges Gaël, Messouna Mohamed, Compaoré Bertrand, Seka Evrard Narcisse, Patricia Agbanglanon, Halima Ahmut, Bouhia Hasnae, Elmajjaoui Sana and Noureddine Benjaafar

    Over the past century, Hodgkin's Lymphoma (HL) has gone from a uniformly fatal disease to a curable disease in approximately 75% of patients worldwide. The selection of therapy should balance the desire to maintain a high rate of cure with the need to minimize long-term complications. In this retrospective study, we propose to report the experience of the management of this pathology to the National Institute of Oncology (INO) in Rabat. We recorded and collected data from 152 patients admitted to the National Institute of Oncology for MDH, the average age is 36.2 +/-16.3 years with extremes of 17 and 81 years. Men made up 52%?? of the total population. The favourable localized stages (IA, IIA) represented 20.4%, we did not have enough data to classify 7 patients. ABVD (Doxorubicin, Bleomycin, Vinblastine, Dacarbazine) was the 1st line protocol in 66% of patients, BEACOPP standard 13.4% (Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone); some have BEACOPPP had the switcher protocol to the BEACOPP standard after 3 cures). 55.9% of patients received between 3 and 6 courses, 17.8% between 7 and 8 courses. 27.2% of patients had curative adjuvant radiotherapy using the irradiation technique (IFRT) Field concerned Radiotherapy with doses of 20 Gy and 30 Gy depending on the response to the initial medical treatment and the initial stage. The median overall survival for all stages was 72.9% after 84 months of follow-up. All-stage event-free survival was 69.3%. The over hall survival according to the favourable localized stages (IA and IIA) was 75.1% higher than that of the unfavourable stages of 71.5% (p=0.186). Patients who had adjuvant radio therapy had overall survival (72.4%) and those who had not been irradiated 72.1% (p=0.733). All-stage event-free survival was 65.1% after 84 months follow-up 95% CI (62.2%-67.9%). Hodgkin lymphoma is a curable malignant tumor in the early and late stages. The treatment should be refined on prognostic models.

    Editorial Pages: 1 - 1

    Antigen Receptor T cell Immunotherapy with Malignant Growth Treatment

    Vincent Amoako-Arhen

    Atomic oncology is an interdisciplinary clinical forte at the interface of therapeutic science and oncology that alludes to the examination of the science of malignant growth and tumors at the sub-atomic scale. Additionally the turn of events and use of atomically focused on treatments. Sub-atomic oncology has distinguished qualities that are associated with the improvement of disease. The examination joined different strategies going from genomics, computational science, tumor imaging, in vitro and in vivo practical models to contemplate natural and clinical aggregates. The proteins delivered by these qualities may fill in as focuses for novel chemotherapy drugs and other malignancy medicines, or imaging checks. Researchers utilize a scope of strategies to approve the part of the novel up-and-comer qualities in the advancement of malignant growth. A definitive point is to make an interpretation of these discoveries into improved therapy choices for disease patients.

    Editorial Pages: 1 - 1

    Strategies for Early Detection of Pancreatic Cancer

    Philipa Amoako

    Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass. These cancerous cells have the ability to invade other parts of the body. A number of types of pancreatic cancer are known. The most common, pancreatic adenocarcinoma, accounts for about 90% of cases, and the term "pancreatic cancer" is sometimes used to refer only to that type. These adenocarcinomas start within the part of the pancreas that makes digestive enzymes. Several other types of cancer, which collectively represent the majority of the nonadenocarcinomas, can also arise from these cells. About 1–2% of cases of pancreatic cancer are neuroendocrine tumors, which arise from the hormoneproducing cells of the pancreas. These are generally less aggressive than pancreatic adenocarcinoma.

    Volume 13, Issue 5 (2021)

      Short Communication Pages: 1 - 1

      Resveratrol suppresses prostate cancer progression in transgenic mice

      Hong Cai

      Resveratrol (trans-3,4’,5-trihydroxystilbene) is a naturally occurring
      antifungal found in a variety of foods including the skin of red grapes and
      peanuts. Since the seminal report that resveratrol could inhibit multiple
      stages of carcinogenesis, it has been the subject of extensive preclinical
      investigations for the treatment and prevention of numerous pathologies
      including cancer, cardiovascular and Alzheimer’s disease, insulin resistance,
      and diabetes . Attempts to translate these findings to humans have increased
      in recent years but there are still fundamental gaps in our understanding of
      the pharmacokinetic pharmacodynamic relations and how plasma/target tissue
      concentrations correlate with clinical efficacy or beneficial effects on health
      maintenance . Such information is needed to inform the choice of optimum
      dose and formulation requirements, and to enhance understanding of the key
      modes of action for resveratrol in each pathology it is also particularly important
      given the notoriously low systemic bioavailability of parent resveratrol due to
      its rapid metabolism, which, if not taken into consideration, would affect its
      clinical utility.

      Short Communication Pages: 1 - 1

      A Compendium of Cancer Therapeutic Strategies and their Modality

      Michael Malfatti

      Pancreatic cancer arises when cells in the pancreas, a glandular organ
      behind the stomach, begin to multiply out of control and form a mass.
      These cancerous cells have the ability to invade other parts of the body. A
      number of types of pancreatic cancer are known.

      Commentary Pages: 1 - 1

      Male Breast Cancer: 37-Year Data Study at a Single Experience Center in Turkey

      Edwina N Scott

      Male breast cancer (MBC) is rare, accounting for less than 1% of all breast cancer and less than 1% of all cancer cases, with less than 0.5% of all cancer deaths in men, annually.MBC usually presents as a firm, painless mass along with palpable axillary nodes, nipple retraction, and ulceration of the skin at presentation. MBC is usually located in the subareolar region, but can also be seen in the upper outer quadrant. As is the case with women, the left breast is involved more predominantly than the right breast, and approximately 1% all of cases are bilateral. Approximately 90% of MBC are invasive ductal carcinomas. Lobular histology is rare, accounting for only 1.5% of MBC. MBC has high rates of hormone-receptor expression; approximately 90% express oestrogen receptor (ER), and 81% express progesterone receptor (PR).

      Commentary Pages: 1 - 2

      New theranostic strategies for drug-induced acute kidney cancer

      Emma Parrott

      Drug-induced predisposition to acute renal failure (ARF) is a facet of nephrotoxicity hitherto mostly uncharacterized, quite underestimated, and impossible to diagnose, which potentially has a high human and socioeconomic impact. Our study has identified urinary GM2AP as the first of a new class of biomarkers of the enhanced risk of suffering an acute renal failure after a subnephrotoxic treatment with gentamicin. Gentamicin-predisposed animals with no sign of renal cancer develop ARF when exposed to a second potentially nephrotoxic drug, also given at subnephrotoxic doses that are harmless to non-predisposed individuals. Subnephrotoxic gentamicin did not alter renal GM2AP gene expression or protein levels, determined by RT-PCR and Western blot and immunostaining, respectively, nor was its serum level modified. Further experiments indicate that, likely, the origin of the increased level of GM2AP in the urine might be a defective tubular handling of this protein as a consequence of gentamicin action.

      Perspective Pages: 1 - 1

      Surgical ovarian ablation for positive women with breast carcinoma in rural India

      Robert G Britton

      Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin. In those with distant spread of the disease, there may be bone pain, swollen lymph nodes, shortness of breath, or yellow skin.

      Volume 13, Issue 6 (2021)

        Case Reports Pages: 1 - 6

        COVID-19 Hepatic Prodromal Syndrome in Patient with Non-Clear Cell Metastatic Renal Cell Carcinoma: A Case Report

        Giovanni Lo Re*, Paolo Doretto, Massimiliano Balbi and Sandro Sulfaro

        DOI: 10.37421/1948-5956.2021.13.482

        Introduction: diagnostic and therapeutic difficulties for cancer are emerging in COVID-19 pandemic. In addition to interstitial pneumonia, disseminated intravascular coagulation and sepsis, liver injury (LI) is a fairly frequent occurrence, with significant weight on evolution and prognosis of COVID-19. Its involvement is linked to cholangiocytes ACE2. Excluded other pathogenesis, LI could represent prodromal phase of COVID-19, if initial diagnostic negativity will be followed by COVID-19 positivity.

        Clinical case: A 59-year-old male patient has diagnosis of metastatic papillary non-clear cell renal cell carcinoma (nccRCC). After neoadjuvant Sunitinib he was submitted to right nephrectomy with caval-atrial thrombectomy in extra-corporeal circulation. Thereafter he continues Sunitinib until disease progression (PD) to bone followed by Axitinib from December 2015 to December 2015 and left femoral radiotherapy (RT) with disease control (DC). After lung and liver PD he was treated with Nivolumab from December 2015 to June 2016 with liver response and overall DC. After liver and caval thrombosis PD, Sorafenib, administered from June 2016 to December 2017, quarterly Zoledronic acid and bone RT obtained DC. Subsequent RT and Cabozantinib from February 2018 to September 2019, during which he reported pathological fracture of left femur, he underwent a surgical reduction and synthesis. From January 2020 to September 2020 Everolimus was administered with DC.

        Subsequently, in light of PD related to immunosuppression, after proven COVID-19 negativity, he started therapy with intravenous low doses Cyclophosphamide, Fluorouracil and subcutaneous Interleukin-2 with moderate toxicity. Following the onset of dyspnea, confirmation of COVID-19 negativity, he was hospitalized and chest CT scan demonstrated size reduction of largest lung lesion. After antibiotic and steroid therapy with clinical improvement and discharge, patient complained symptoms worsening and biochemistry showed cholestatic hepatitis signs and INR lengthening. During subsequent hospitalization, he experienced rectorrhagia and biohumoral tests shown negativity for COVID-19, hypo-albumin, and persistence of coagulative and hepatic disorders. Change of immunological parameters, from which lymphocyte immunophenotype with initial increase of Treg counts followed by decrease during chemo-immunotherapy were observed. Despite support care, patient died with nasopharyngeal swab COVID-19 positivity.

        Conclusion: This prodromal hepatic picture in heavy treated nccRCC could be an expression of increase of T lymphocytes and Treg counts, stimulated by IL-2, with negative feedback on hyper-inflammation, linked to hyper-cytokinemia, with attempt to control viral infection. It result in the delaying of the disease course whereas failure with lymphocyte and Treg reduction count culminates with final worsening until COVID-19 positivity.

        Case Report Pages: 1 - 4

        Leptomeningeal Metastases in Nasopharyngeal Carcinoma: A Rare Case Report and a Review of Literature

        El Amin Marnouche*, Khalid Hadadi, Abdelhak Maghous, Maroua Benlemlih, Mouhcine Hommadi, Mohamed Oukabli, Khalid Saghir Andaloussi, Mohamed Elmarjany and Hassan Sifat

        DOI: 10.37421/1948-5956.2021.13.483

        Introduction: The most common sites for distant nasopharyngeal carcinoma metastases are the bone, lung, and liver. Leptomeningeal metastases LM in undifferentiated nasopharyngeal carcinoma are rare.

        Case and outcomes: We present a case report of a 36 years old patient treated initially for undifferentiated nasopharyngeal carcinoma (T2N3M0, stage III of AJCC 7th edition) by association of chemotherapy and radiotherapy. Two years and half later, the patient developed a frontal leptomeningeal metastasis in association with subcutaneous and left parotid relapses on MRI. The patient was treated by resection of the leptomeningeal and subcutaneous lesions. These masses turned out to be an undifferentiated carcinoma consistent with nasopharyngeal carcinoma metastasis. The patient refused parotidectomy and adjuvant radiotherapy of leptomeningeal metastasis was performed. She is now being treated with chemotherapy.

        Discussion: Leptomeningeal metastases from nasopharyngeal carcinoma are rare and occur in almost 3% of patients. Multifocal neurologic signs are common and indicate multilevel involvement. The treatment of LM is based on chemotherapy and radiation therapy. Even with chemotherapeutic agents active on central neurologic system, the median survival was up to four months.

        Conclusion: Leptomeningeal metastases from NPC are rare. The prognosis of patients with LM is poor. However a small subset of patients with low tumor burden and good performance status could be treated more aggressively with multimodal strategy.

        Research Article Pages: 1 - 4

        Clinical Features, Prognostic Factors and Treatment Outcome of Chondroblastic Osteosarcoma: A Single-Center Experience

        Feryel Letaief Ksontini*, Yosr Zenzri, Zahra Ghodhbani, Azza Gabsi, Mouna Ayadi and Amel Mezlini

        DOI: 10.37421/1948-5956.2021.13.484

        Objective: Chondroblastic osteosarcoma is an aggressive bone cancer with poor outcome accounting for 25% of cases of conventional osteosarcoma. The aim of our study was to assess the clinico-epidemiological profile, prognostic factors, and treatment outcome of chondroblastic osteosarcoma.

        Methods: A monocentric retrospective study was conducted between 1982 and 2020. Data of chondroblastic osteosarcoma patients treated in Salah Azaïz Institute were collected. Patient's treatment variables, prognostic factors and and treatment outcome were assessed.

        Results: Thirty patients were included. Most of them (n=24) were younger than 25 years. Femur (n=15) and tibia (n=8) were the most common sites involved. Twenty patients had localized disease and 10 patients had metastatic disease on presentation. Neoadjuvant chemotherapy was performed in 23 patients. They received combination regimen of methotrexate, adrimaycin and cisplatin (MAP) (44%), methotrexate, etoposide and ifosfamide (30%), combined doxorubicin-ifosfamide-cisplatin (API) and doxorubicinifosfamide (AI) (22%), etoposide, ifosfamide and cisplatin (VIP) (4%). 16% of patients had partial response, 63% a clinical progression and 21% patients a stable disease. Surgery was performed in 22 patients. Of 16 patients operated, 4 (25%) were good responders while 12 (75%) were poor responders. For patients with metastatic disease, only one achieved complete remission. Six patients progressed after treatment and two died. For patients with localized osteosarcoma, 6 patients had local recurrence and 6 patients had distant metastases. Median overall survival was 35 months. Overall survival at 2 years was 43%. Median disease free survival was 12 months. Disease free survival at 2 years was 21%. The absence of clinical response after neoadjuvant chemotherapy and age> 25 years were prognostic factor influencing disease-free-survival (p=0.025 and p=0.012, respectively).

        Conclusion: Chondroblastic osteosarcoma is an aggressive tumor with a tendency for local recurrence and distant metastasis. Younger onset age and response to neoadjuvant chemotherapy can predict better disease free survival.

        Volume 13, Issue 2 (2021)

          Case Report Pages: 1 - 4

          Non- Seminoma Testicular Tumors Clinical Stage I: Management Strategies

          Rajendra Nerli

          Clinical stage I is the most frequent clinical presentation of non-seminoma testicular cancer. Despite a survival rate of close to 100%, the management of patients with this disease stage is controversial. The recurrence rate is 15% to 50% for those with stage I non-seminoma. A highly sensitive and specific biomarker that can predict or confirm relapse of disease, and help to drive a definitive risk-adapted management is still not available. Lymph vascular invasion (LVI) in the orchiectomy specimen has been used as a risk factor in patients with stage I non-seminoma, however, the discriminative power of LVI is modest at best. Presently there is no definitive biomarker that can predict a recurrence following a radical orchiectomy. In situations such as this, active surveillance of these patients helps avoid overtreatment in 50% to 85% of patients, with no risk of long-term side effects in non-relapsing patients and a preserved overall survival of almost 100% after specific treatment for recurrent disease. Although active surveillance has been accepted as the preferred option for stage I low-risk non-seminoma, its role in high-risk stage I non-seminoma remains controversial.
          Mini Review Pages: 1 - 5

          Use of Enzalutamide in Carcinoma Prostate

          Rajendra Nerli

          Patients with metastatic prostate cancer are initially treated with androgen deprivation therapy as androgen receptor (AR) signalling is a key pathway in prostate cancer. Castration-resistant prostate cancer (CRPC) is a stage when patients stop responding to androgen deprivation therapy but are still dependent on AR signalling. Enzalutamide, an orally available AR inhibitor, was initially used in the treatment of patients with metastatic CRPC who had previously received docetaxel. The indications have subsequently been extended to include all patients with metastatic CRPC, and most recently to include patients with non-metastatic CRPC. On December 16, 2019, the Food and Drug Administration approved enzalutamide for patients with metastatic castration-sensitive prostate cancer (mCSPC). The most common adverse reactions that have been reported in enzalutamide-treated patients include hot flushes, asthenia/fatigue, hypertension, fractures, and musculoskeletal pain. The recommended dose is 160 mg (four 40 mg capsules) administered orally once daily, with or without food.
          Case Report Pages: 1 - 5


          Rajendra Nerli

          A renal mass/Renal cell carcinoma has a range of histologies and tumour phenotypes that it presents with a particular challenge to treat them. A renal mass can range from benign (oncocytoma) to a clinically indolent malignancy (papillary type I, chromophobe) to aggressive disease [papillary type II or high-grade clear cell renal cell carcinoma (ccRCC)]. Even among various subtypes, kidney cancers are genetically diverse with variable prognoses and treatment response rates. The key to proper management depends on the identification of these subtypes. Currently, a wide array of diagnostic, prognostic, and predictive biomarkers are available to help guide the individualized care of kidney cancer patients. This paper discusses the various serum, urine, and imaging biomarkers that are available in practice
          Research Article Pages: 1 - 8

          Integration of Chemotherapy with Brachytherapy in the Treatment of Locally Advanced Uterine Cervical Cancer

          Aishwarya Raj

          Carcinoma of Uterine cervix is the second most common cancer affecting females in India. Concurrent chemoradiation has remained the sole definitive treatment available in the locally advanced stages. Our study was planned to take the advantage of radiosensitisation accruing due to chemotherapy at the time of brachytherapy when approximately forty percent of total tumour dose is applied.Study design was prospective, randomized and comparative.100 patients with locally advanced squamous cell carcinoma of cervix (FIGO stage IIB to IVA) were included from 2017 to 2019 and divided into two arms of 50 patients each as per computer generated random number list .All were given concurrent chemoradiation followed by 3 insertions of brachytherapy as per the Manchester System, each application was 7Gy by HDR. Patients in Arm A (Study Arm) received cisplatin 40mg/m2 along with EBRT and brachytherapy and Arm B (Control Arm) received cisplatin 40mg/m2 along with EBRT only.
          Case Report Pages: 1 - 3

          Penile Metastasis from Cancer of Prostate: A Case Report

          Rajendra Nerli

          Metastatic spread from the prostate to the penis is known to occur, though rare. A needle biopsy remains the most reliable diagnostic modality that allows for histological and immunological confirmation of metastatic spread, and evaluation of the extent of invasion. The mode of metastasis seems to be either by direct invasion, implantation, haematogenous or lymphatic spread. Treatment mainly remains palliative and improving quality of life in view of the poor prognosis and a 6-month mortality of 80%. We report a patient with castrate resistant prostate cancer who presented with obstructive voiding symptoms and reddish lesions on the glans. Biopsy proved it to be a metastasis from the prostate cancer.

          Volume 13, Issue 3 (2021)

            Editorial Pages: 1 - 1

            Bone Marrow Can Give Rise to Hematopoietic Lineage Cells

            Sizwe Singwane

            Bone marrow is a semi-strong tissue found inside the light or chancellors parts of bones. In birds and well evolved creatures, bone marrow is the essential site of fresh blood cell creation or haematopoiesis. It is made out of hematopoietic cells, marrow fat tissue, and steady stromal cells. In grown-up people, bone marrow is fundamentally situated in the ribs, vertebrae, sternum, and bones of the pelvis. Bone marrow includes roughly % of complete weight in sound grown-up people, to such an extent that a man gauging kg ( lbs) will have around . kg ( lbs) of bone marrow.

            Editorial Pages: 1 - 1

            Malignant Fibrous Histiocytoma and Liposarcoma Treatment

            Cheng Zin

            A sarcoma is a threatening tumor, a sort of disease that emerges from changed cells of mesenchyme (connective tissue) origin. Connective tissue is an expansive term that incorporates bone, ligament, fat, vascular, or hematopoietic tissues, and sarcomas can emerge in any of these kinds of tissues. Sub-sequently, there are numerous subtypes of sarcoma, which are arranged dependent on the particular tissue and kind of cell from which the tumor originates. Sarcomas are essential connective tissue tumors, implying that they emerge in connective tissues. This is as opposed to optional (or "metastatic") connective tissue tumors, which happen when a malignant growth from somewhere else in the body (like the lungs, bosom tissue or prostate) spreads to the connective tissue. Causes and danger factors.

            Perspective Pages: 1 - 1

            Carcinomas can be Authoritatively Analysed Through Biopsy

            Shirley Kolata

            Carcinomas are normally organized with Roman numerals. In many arrangements, Stage I and Stage II carcinomas are affirmed when the tumour has been discovered to be little or potentially to have spread to nearby constructions as it were. Stage III carcinomas regularly have been found to have spread to provincial lymph hubs, tissues, or potentially organ structures, while Stage IV tumours have effectively metastasized through the blood too far off destinations, tissues, or organs. Carcinoma is a threat that creates from epithelial cells. In particular, a carcinoma is a malignancy that starts in a tissue that lines the inward or external surfaces of the body, and that emerges from cells beginning in the endodermal, mesodermal or ectodermal germ layer during embryogenesis.

            Commentary Pages: 1 - 1

            Clinical Order Explicitly gave to Pharmacotherapy for Malignancy

            Qingbing Zhao

            Chemotherapy (frequently shortened to chemo and now and then CTX or CTx) is a sort of malignant growth therapy that utilizes at least one enemy of disease drugs (chemotherapeutic specialists) as a component of a normalized chemotherapy routine. Chemotherapy might be given with a corrective plan (which quite often includes mixes of medications), or it might intend to drag out life or to decrease manifestations (palliative chemotherapy). Chemotherapy is one of the significant classifications of the clinical order explicitly gave to pharmacotherapy for malignancy, which is called clinical oncology.

            Research Pages: 1 - 3

            Prior Telephone Confirmation to Reduce Absenteeism in Oncological Surgeries: A Phone Call That Saves Lives

            Irami Araújo-Filho*, Danielly Acioli Galvão de Souza, Joseli Soares Brazorotto and Erika Maria Araújo Barbosa de Sena

            n assessing the quality of health services, the use of quality and resolution indicators used in the operating room stands out. The cancellation fee for operating procedures is one of the most important. Cancellations interfere with the outcome of care and increase hospital costs. In the case of cancer patients, the consequences are severe, since early surgical intervention directly influences prognosis, reducing morbidity, and mortality. Considering that surgical suspensions should be prevented, pre-anesthetic consultation and telephone confirmation days before the procedure configure strategies that can be adopted to minimize the problem. A descriptive observational study with a quantitative approach was conducted on the impact of previous telephone confirmation on the reduction of cancellation of oncologic surgeries due to absenteeism. The research was carried out at Professor Alberto Antunes University Hospital, Federal University of Alagoas (HUPAA/UFAL), city of Maceió, State of Alagoas, Northeastern Brazil. The sample consisted of 205 patients with scheduled cancer surgery from January to June 2019, after approval by the Institutional Ethics Committee. Data analysis was performed descriptively. The effectiveness of previous telephone confirmation was verified, with a 50% reduction in cancellation of elective oncologic surgeries due to absenteeism. The implementation of a call center to confirm the presence of the user consisted of an impact strategy in reducing the cancellation of previously scheduled cancer surgeries.

          Relevant Topics

Indexed In



tempobet giriş

tempobet giriş


tipobet yeni giriş adresi tipobet e yeni giriş tipobet güncel giriş adresi imajbet giriş adresi

mobilbahis giriş

arrow_upward arrow_upward